Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
30 hedge funds and large institutions have $17.2M invested in Astria Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 7 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
3.67% less ownership
Funds ownership: 47.7% → 44.03% (-3.7%)
9% less funds holding
Funds holding: 33 → 30 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
59% less capital invested
Capital invested by funds: $41.7M → $17.2M (-$24.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.24M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$340K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$224K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$106K |
| 5 |
Millennium Management
New York
|
+$75.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$3.62M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.25M |
| 3 |
D.E. Shaw & Co
New York
|
-$166K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$131K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$107K |
ATXS Hedge Fund Activity: Q2 2022 in Review
30 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2022, worth a combined $17.2M — down 59% from $41.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ATXS and 4 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Ikarian Capital, adding an estimated $2.24M. The largest seller was VR Adviser, exiting entirely with an estimated $3.62M sold.
- 30 institutional investors held Astria Therapeutics (ATXS) as of Q2 2022, down from 33 in Q1 2022.
- Funds reported $17.2M of Astria Therapeutics stock for Q2 2022, down 59% quarter-over-quarter.
- 4 funds opened new Astria Therapeutics positions in Q2 2022 and 7 closed out, a net change of -3 holders.
- The largest Astria Therapeutics buyer in Q2 2022 was Ikarian Capital, an estimated $2.24M added.
- The largest Astria Therapeutics seller in Q2 2022 was VR Adviser, an estimated $3.62M sold.
Based on aggregated 13F filings for Q2 2022.